Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Patent
1995-05-24
1999-03-30
Draper, Garnette D.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
530395, 424 851, 930144, C07K 14525
Patent
active
058891560
ABSTRACT:
A virion expression system for a desired protein packaged in an envelope derived from a retrovirus useful in administering proteins which cross cell membranes in order to serve their function. Preferred virions are those that carry an RNA sequence that encodes cytokines or lymphokines, and includes IL-2, multiple drug resistance protein, and TNF.
REFERENCES:
patent: 4405712 (1983-09-01), Vande Woude et al.
patent: 4518584 (1985-05-01), Mark et al.
patent: 4603112 (1986-07-01), Paoletti et al.
patent: 4650764 (1987-03-01), Temin et al.
patent: 4663281 (1987-05-01), Gillies et al.
patent: 4677063 (1987-06-01), Mark et al.
patent: 4678751 (1987-07-01), Goeddel
patent: 4708818 (1987-11-01), Montanier et al.
patent: 4725669 (1988-02-01), Essex et al.
patent: 4769330 (1988-09-01), Paoletti et al.
patent: 4847201 (1989-07-01), Kaswasaki et al.
patent: 4861719 (1989-08-01), Miller
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4868119 (1989-09-01), Clark et al.
patent: 4879226 (1989-11-01), Wallace et al.
patent: 4894439 (1990-01-01), Dorin et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 4980289 (1990-12-01), Temin et al.
patent: 4990455 (1991-02-01), Yamagishi et al.
patent: 5028420 (1991-07-01), Masegi et al.
patent: 5081021 (1992-01-01), Mizuno et al.
patent: 5091309 (1992-02-01), Schesinger et al.
patent: 5206352 (1993-04-01), Roninson et al.
patent: 5246924 (1993-09-01), Fox et al.
patent: 5262309 (1993-11-01), Nakimura et al.
patent: 5288552 (1994-02-01), Yamada et al.
patent: 5304489 (1994-04-01), Rosen
patent: 5306631 (1994-04-01), Harrison et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5487984 (1996-01-01), Allet et al.
Rosenberg et al., "Gene Transfer Into Humans--Immunotherapy of Patients With Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction," The New England Journal of Medicine, 323(9):570-578 (Aug. 30, 1990).
Hwu et al., "Functional and Molecular Characterization of Tumor-Infiltrating Lymphocytes Transduced with Tumor Necrosis Factor-.alpha. cDNA for the Gene Therapy of Cancer in Humans," J. Immunol., 9(1):4104-4115 (1993).
Rosenberg, S.A., "Gene Therapy for Cancer," JAMA, 268(17):2416-2419 (1992).
Rosenberg, et al., "The Development of Gene Therapy for The Treatment of Cancer," Annals of Surgery 218(4):455-464 (1993).
Annual Report for 1995, IND Application to the FDA by Division of Cancer Treatment, Diagnosis and Centers, National Cancer Institute, "TNF-Transduced Tumor Infiltrating Lymphocytes With Or Without Interleukin-2" Serial No. 14, Jan. 22, 1996.
Rosenberg S.A., "The Immunotherapy and Gene Therapy of Cancer," J. of Clinical Oncology 10:(2):180-199 (Feb. 1992).
Miller et al., "Redesign of Retrovirus Packaging Cell Lines To Avoid Recombination Leading to Helper Virus Production," Molecular And Cellular Biology, 6(8):2895-2902 (Aug. 1986).
Kowalski et al., "Functional Regions of the Envelope Glycoprotein of Human Immunodeficiency Virus Type 1," Science, 237:1351-1355 (Sep. 11, 1987).
Rosenberg, S.A., "Adoptive Immunotherapy for Cancer," Scienctific American, pp. 62-69 (May 1990).
Ueda et al., Proc. Nat. Acad. Sci. 84:3004-3008 (1987).
Yamada et al., EMBO J. 6(9):2705-2709 (1987).
Aggarwal et al., "Human Tumor Necrosis Factor," J. Biol. Chem., 260(4):2345-2354 (Feb. 25, 1985).
Anderson, W.F., "Prospects for Human Gene Therapy," Science, 226:401-409 (Oct. 26, 1984).
Belldegrum et al., "Interleukin 2 Expanded Tumor-infiltrating Lymphocytes in Human Renal Cell Cancer: Isolation, Characterization, and Antitumor Activity," Cancer Research, 48:206-214 (Jan. 1, 1988).
Bender et al., "Evidence that the Packaging Signal of Maloney Murine Leukemia Virus Extends into the gag Region," J. Virol., 61(5):1639-1646 (May, 1987).
Beutler et al., "Purification of Cachectin, A Lipoprotein Lipase-Suppressing Hormone Secreted by Endotoxin-Induced RAW 264.7 Cells," J. Exp. Med., 161:984-995 (May, 1985).
Beutler et al., "Identity of Tumor Necrosis Factor and the Macrophage-Secreted Factor Cachectin," Nature, 316:552-554 (Aug., 1985).
Carswell et al., "An Endotoxin Induced Serum Factor that Causes Necrosis of Tumors," Proc. Nat'l Acad. Sci., USA, 72(9):3666-3670 (Sep., 1975).
Clewell, D.B., "Nature of Col E.sub.1 Plasmid Replication in Escherichia coli in the Presence of Chloramphenicol," J. Bacteriol., 110(2):667-676 (May, 1972).
Clewell, et al., "Supercoiled Circular DNA-Protein Complex in Escherichia coli: Purification and Induced Conversion to an Open Circular DNA Form," Proc. Nat'l Acad. Sci., USA, 62:1159-1166 (1969).
Coffin, J., Genome Structure, In: RNA Tumor Viruses, vol. 2, Weiss et al., (Eds.), 2nd Edition, Cold Spring Harbor Monograph Series, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, pp. 17-73.
Cohen et al., "Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation of Escherichia coli by R-Factor DNA," Proc. Nat'l Acad. Sci., USA, 69(8):2110-2114 (Aug., 1972).
Cone et al., "High-efficiency Gene Transfer into Mammalian Cells: Generation of Helper-free Recombinant Retrovirus With Broad Mammalian Host Range," Proc. Nat'l Acad. Sci., USA, 81:6349-6353 (Oct., 1984).
Graham & Van Der Eb, "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA," Virology, 52:456-467 (1973).
Gray et al., "Expression of Human Immune Interferon cDNA in E. coli and Monkey Cells," Nature, 295:503-508 (Feb. 11, 1982).
Jacobs et al., "Molecular Cloning, Sequencing, and Expression in Escherichia coli of Human Preprourokinase cDNA," DNA, 4(2):139-146 (1985).
Kriegler et al., "Transformation Mediated by the SV40 T Antigens: Separation of the Overlapping SV40 Early Genes with a Retroviral Vector," Cell, 38:483-491 (Sep., 1984).
Lang et al., "Expression of a Hemopoietic Growth Factor cDNA in a Factor-Dependent Cell Line Results in Autonomous Growth and Tumorigenicity," Cell, 43:531-542 (Dec., 1985).
Maniatis et al., Molecular Cloning :A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, pp. 252-253 (1982).
Mann et al., "Construction of a Retrovirus Packaging Mutant and Its Use to Produce Helper-Free Defective Retrovirus," Cell, 33:153-159 (May, 1983).
Matteucci et al., "Synthesis of Deoxyoligonucleotides on a Polymer Support," J. Am. Chem. Soc., 103:3185-3191 (1981).
Maxam et al., "Sequencing End-Labeled DNA with Base-Specific Chemical Cleavages," Meth. Enzymol., 65:499-561 (1980).
McCormick, D., "Human Gene Therapy: The First Round," Bio/Technology, 3:689-693 (1985).
Messing et al., "New M13 Vectors for Cloning," Methods in Enzymology, 101:20-78 (1983).
Miller et al., "Improved Retroviral Vectors for Gene Transfer and Expression," BioTechniques, 7(9):980-988 (1989).
Miller et al., "Retrovirus-mediated Gene Transfer into Human Skin Fibroblasts," In: Current Communications in Molecular Biology, pp. 122-127 (1988).
Pennicia et al., "Human Tumor Necrosis Factor: Precursor, Structure, Expression, and Homology to Lymphotoxin," Nature, 312:724-729 (1984).
Rosenberg et al., "Use of Tumor Infiltrating Lymphocytes and Interleukin-2 in Immunotherapy of Patients with Metastatic Melanoma," New England Journal of Medicine, 319:1676-1680 (Dec. 22, 1988).
Rosenberg et al., "A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes," Science, 233:1318-1321 (Sep. 19, 1986).
Sanger et al., "DNA Sequencing with Chain-Terminating Inhibitors," Proc. Nat'l Acad. Sci., USA, 74(12):5463-5467 (Dec., 1977).
Smith, et al., "In Vitro Mutagenesis," Ann. Rev. Genet., 19:423-462 (1985).
Southern et al., "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promotor," J. Mol. Appl. Gen., 1:327-341 (1982).
Topalian et al., "Immunotherapy of Patients with Advanced Cancer Using Tumor-infiltrating Lymphocytes and Recombinant Interleukin-2: A Pilot Study," J. Clin. Oncol., 6:839-853 (1988).
Wang et al., "Molecular Cloning of the Complementary DNA for Human Tumor Necrosis Factor," Science, 228:149-154 (Apr. 12, 1985).
Weck et al., "Antiviral Activities of Hybrids of Two Major Human Leukocyte Inter
Kriegler Michael
Perez Carl F.
Blackburn Robert P.
Chiron Corporation
Draper Garnette D.
Kruse Norman J.
Pochopien Donald
LandOfFree
TNF deletion muteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TNF deletion muteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TNF deletion muteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1216269